Literature DB >> 27787407

Vasodilators in Septic Shock Resuscitation: A Clinical Perspective.

Thiago Domingos Corrêa1, Roberto Rabello Filho, Murillo Santucci Cesar Assunção, Eliézer Silva, Alexandre Lima.   

Abstract

Microcirculatory abnormalities have been shown to be frequent in patients with septic shock despite "normalization" of systemic hemodynamics. Several studies have explored the impact of vasodilator therapy (prostacyclin, inhaled nitric oxide, topic acetylcholine, and nitroglycerin) on microcirculation and tissue perfusion, with contradictory findings.In this narrative review, we briefly present the pathophysiological aspects of microcirculatory dysfunction, and depict the evidence supporting the use of vasodilators and other therapeutic interventions (fluid administration, blood transfusion, vasopressors, and dobutamine) aiming to improve the microcirculatory flow in septic shock patients.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27787407     DOI: 10.1097/SHK.0000000000000777

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  3 in total

Review 1.  Hypothesis: Fever control, a niche for alpha-2 agonists in the setting of septic shock and severe acute respiratory distress syndrome?

Authors:  F Petitjeans; S Leroy; C Pichot; A Geloen; M Ghignone; L Quintin
Journal:  Temperature (Austin)       Date:  2018-05-22

2.  Effects of nitroglycerin versus labetalol on peripheral perfusion during deliberate hypotension for sinus endoscopic surgery: a randomized, controlled, double-blinded trial.

Authors:  Marwa Zayed; Heba Nassar; Ahmed Hasanin; Amany H Saleh; Passaint Hassan; Dalia Saad; Sahar Mahmoud; Ghada Abo Bakr; Eman Fouad; Norhan Saleh; Maha Ismail; Hani El-Hadi
Journal:  BMC Anesthesiol       Date:  2020-04-17       Impact factor: 2.217

3.  Distribution and relative expression of vasoactive receptors on arteries.

Authors:  Xinhao Liu; Dan Luo; Jie Zhang; Lei Du
Journal:  Sci Rep       Date:  2020-09-21       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.